Non invasive neuromodulation device for Parkinson Disease
Phase-Based Progress Estimates
Effectiveness
Safety
University of Michigan, Ann Arbor, MI
Parkinson Disease
Non invasive neuromodulation device - DeviceEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This study investigates whether vestibular (inner ear) dysfunction is a cause for poor balance in Parkinson Disease (PD), and whether inner ear stimulation with a small device may improve balance. This study will involve clinical testing, brain imaging, and an interventional treatment device for symptoms.
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: after a week of treatment
after a week of treatment
Freezing of Gait
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Active Intervention
1 of 2
Sham Intervention
1 of 2
Experimental Treatment
Non-Treatment Group
64 Total Participants · 2 Treatment Groups
Primary Treatment: Non invasive neuromodulation device · Has Placebo Group · N/A
Active Intervention
Device
Experimental Group · 1 Intervention: Non invasive neuromodulation device · Intervention Types: DeviceSham Intervention
Device
ShamComparator Group · 1 Intervention: Non invasive neuromodulation device (sham) · Intervention Types: DeviceTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: after a week of treatment
Closest Location: University of Michigan · Ann Arbor, MI
2022First Recorded Clinical Trial
17 TrialsResearching Parkinson Disease
1005 CompletedClinical Trials
Who is running the clinical trial?
University of MichiganLead Sponsor
1,597 Previous Clinical Trials
6,328,993 Total Patients Enrolled
19 Trials studying Parkinson Disease
1,414 Patients Enrolled for Parkinson Disease
US Department of Veterans AffairsFED
853 Previous Clinical Trials
470,746 Total Patients Enrolled
14 Trials studying Parkinson Disease
926 Patients Enrolled for Parkinson Disease
Eligibility Criteria
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments